| Malignant neoplasm of breast

Kisqali vs Arimidex

Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.

Deep comparison between: Kisqali vs Arimidex with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsArimidex has a higher rate of injection site reactions vs Kisqali based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Arimidex but not Kisqali, including UnitedHealthcare

Category

Kisqali

Arimidex

At A Glance

RouteOral

FrequencyOnce daily (21/28-day cycle)

ClassCDK4/6 inhibitor

RouteOral

FrequencyDaily

ClassAromatase inhibitor

Indications

Malignant neoplasm of breast
Advanced breast cancer

Malignant neoplasm of breast
Locally advanced breast cancer
Carcinoma breast stage IV

Dosing

Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.

Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.

Malignant neoplasm of breast 1 mg tablet orally once daily; adjuvant treatment duration in the ATAC trial was 5 years.

Locally advanced breast cancer, Carcinoma breast stage IV 1 mg tablet orally once daily; continue until tumor progression.

Contraindications

—

Hypersensitivity to anastrozole or any excipient (including anaphylaxis, angioedema, and urticaria)

Drug Interactions

1170View drug interactions

918View drug interactions

Adverse Reactions

Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain

Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia

Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS

Most common (>=10%) Hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, lymphedema

Serious Skin lesions, ulcers, or blisters; severe allergic reactions with swelling of face, lips, tongue, and/or throat; liver function abnormalities including hepatitis

Postmarketing Hepatobiliary events (increases in alkaline phosphatase, ALT, AST, gamma-GT, and bilirubin; hepatitis), erythema multiforme, Stevens-Johnson syndrome, angioedema, urticaria, anaphylaxis, myalgia, hypercalcemia, tendon disorders including tendon rupture and tendonitis

Pharmacology

Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.

Anastrozole is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme, significantly lowering serum estradiol concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone formation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Kisqali